Lifeward Secures $5.6M Convertible Funding

Lifeward Secures $5.6M Convertible Funding

Lifeward Ltd. (NASDAQ:LFWD) saw its shares rise 5.6% in after‑hours trading on Tuesday, July 6, 2026, after the company disclosed that it had raised $5.6 million through senior secured convertible notes accompanied by warrants. The financing was executed under a securities purchase agreement with institutional and accredited investors and is part of a strategic framework previously established with Oramed Pharmaceuticals (NASDAQ:ORMP).

The initial closing delivered approximately $5.6 million in senior secured convertible notes. A second tranche of an equal amount, $5.6 million, will become available only if Lifeward meets one of two commercial milestones: either a 150% increase in ReWalk unit sales over the trailing twelve‑month period, or the company’s shares trading at or above $13.80 for ten consecutive trading days.

The partnership with Oramed provides Lifeward access to up to $47 million of total financing under the framework, of which the first $10 million has already been funded. This capital is intended to strengthen Lifeward’s ability to accelerate commercialization of its restorative healthcare platform, expand its reimbursement‑backed distribution model, and advance its product pipeline.

Lifeward’s current product portfolio comprises the ReWalk Exoskeleton, the AlterG Anti‑Gravity system, the MyoCycle Functional Electrical Stimulation (FES) System, and the ReStore Exo‑Suit. In addition, the company is developing a Protein Oral Delivery platform, with lead candidate ORMD‑0801 aimed at the diabetes market.

Mark Grant, President and Chief Executive Officer of Lifeward, said the financing reflects confidence in the company’s strategy and will enable faster commercialization of its technologies.